Article
Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.
The Journal of dermatology - 1 Apr 2018
Yamazaki Naoya, Tsutsumida Arata, Takahashi Akira, Namikawa Kenjiro, Yoshikawa Shusuke, Fujiwara Yutaka, Kondo Shunsuke, Mukaiyama Akihira, Zhang Fanghong, Kiyohara Yoshio
Abstract excerpt
The combination of dabrafenib and trametinib demonstrated encouraging antitumor activity and tolerability, at initial analysis, in Japanese patients with BRAF V600 mutant advanced melanoma warranting further investigation. This study evaluated the safety and tolerability, pharmacokinetics (PK) and preliminary efficacy of dabrafenib 150 mg b.i.d. plus trametinib 2 mg q.d. in Japanese patients with BRAF V600E/K...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.